<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05016882</url>
  </required_header>
  <id_info>
    <org_study_id>NN9500-4656</org_study_id>
    <secondary_id>U1111-1255-5551</secondary_id>
    <secondary_id>2020-003566-39</secondary_id>
    <nct_id>NCT05016882</nct_id>
  </id_info>
  <brief_title>Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>Efficacy and Safety Investigation of NNC0194-0499 Co-administered With Semaglutide in Subjects With Non-alcoholic Steatohepatitis: a Dose-ranging, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and&#xD;
      semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).&#xD;
&#xD;
      NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known&#xD;
      medicine, which is already used by doctors to treat type 2 diabetes in many countries. It&#xD;
      also helps with weight loss and may reduce liver damage, and so prevent future liver&#xD;
      complications. It works in a different way to NNC0194 0499. The 2 medicines may work better&#xD;
      together than on their own.&#xD;
&#xD;
      The study will also look at a combination of semaglutide and another weight-loss medicine&#xD;
      called NNC0174-0833, which may be another treatment option for NASH.&#xD;
&#xD;
      Each week, participants will get 2 injections. These could be 2 of the 3 medicines OR 1 of&#xD;
      the medicines and a placebo OR 2 placebo injections. Which treatment participants get is&#xD;
      decided by chance. A placebo is a dummy medicine which looks like the real medicine but&#xD;
      doesn't contain any active medicine.&#xD;
&#xD;
      The study will last for about 19 months. Participants will have 14 clinic visits and 9 phone&#xD;
      calls with the study doctor.&#xD;
&#xD;
      Participants will have 1 or 2 liver biopsies (tiny pieces of liver tissue) - one at the start&#xD;
      (if participants have not had a biopsy recently) and one at the end of the study treatment.&#xD;
&#xD;
      Women: Women cannot take part if pregnant, breast-feeding or planning to become pregnant&#xD;
      during the study period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2021</start_date>
  <completion_date type="Anticipated">September 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 8, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomised, double-blind, active and placebo-controlled, double-dummy, parallel group, multinational trial investigating NNC0194-0499 at 3 different dose levels when co administered with semaglutide</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in liver fibrosis and no worsening of NASH (Yes/No)</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Count of subjects Improvement in fibrosis is defined as greater than or equal to 1 grade improvement on the NASH CRN fibrosis scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No)</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Count of subjects Resolution of steatohepatitis is defined as a NAS of 0-1 for inflammation, 0 for ballooning and any value for steatosis according to NASH CRN52. Fibrosis is graded on the NASH CRN (Non-Alcoholic Steatohepatitis Clinical Research Network) fibrosis scale from 0 to 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in steatohepatitis with at least a 2-point reduction in NAS and no worsening of fibrosis (Yes/No)</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Count of subjects The 2-point reduction must include at least a 1-point reduction in either lobular inflammation or hepatocellular ballooning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in histology-assessed liver collagen proportionate area</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Ratio to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolution of steatohepatitis and improvement in liver fibrosis (Yes/No)</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Count of subjects Resolution of steatohepatitis is defined as an NAS score of 0-1 for inflammation, 0 for ballooning and any value for steatosis (according to NASH CRN).&#xD;
Improvement in fibrosis is defined as greater than or equal to 1 grade improvement on the NASH CRN fibrosis scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in liver fibrosis (Yes/No)</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Count of subjects Improvement in fibrosis is defined as greater than or equal to 1 grade improvement on the NASH CRN fibrosis scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of liver fibrosis (Yes/No)</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Count of subjects For subjects with fibrosis stage 2 or 3 at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Worsening in steatohepatitis (Yes/No)</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Count of subjects Worsening in steatohepatitis is defined as increase in NAS score for ballooning, inflammation or steatosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in ballooning (Yes/No)</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Count of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in inflammation (Yes/No)</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Count of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in steatosis (Yes/No)</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Count of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ALT (alanine aminotransferase)</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Ratio to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AST (aspartate aminotransferase)</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Ratio to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in inflammation assessed by HsCRP (high sensitivity C-reactive protein)</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Ratio to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ELF (Enhanced Liver Fibrosis) score</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Logarithm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c. For subjects with type 2 diabetes</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>%-points (absolute change)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in triglycerides</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Ratio to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in free fatty acids</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Ratio to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL (low density lipoprotein) cholesterol</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Ratio to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HDL (high density lipoprotein) cholesterol</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Ratio to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in body weight</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36 (36-item Short Form Survey) bodily pain</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NASH-CHECK (patient-reported outcome measure for non-alcoholic steatohepatitis)pain</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PROMIS (Patient-Reported Outcomes Measurement Information System) Fatigue score</measure>
    <time_frame>From baseline (week 0) to week 52</time_frame>
    <description>Points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>From baseline (week 0) to week 59</time_frame>
    <description>Count</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">672</enrollment>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>NNC0194-0499 7.5 mg + semaglutide 2.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (NNC0194-0499) 7.5 mg + semaglutide placebo 2.4 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC0194-0499 15 mg + semaglutide 2.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (NNC0194-0499) 15 mg + semaglutide placebo 2.4 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC0194-0499 30 mg + semaglutide 2.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC0194-0499 30 mg + semaglutide placebo 2.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (NNC0194-0499) 30 mg + semaglutide 2.4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (NNC0194-0499) 30 mg + semaglutide placebo 2.4 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NNC0174-0833 2.4 mg + semaglutide 2.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (NNC0174-0833) 2.4 mg + semaglutide placebo 2.4 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0194 0499 50 mg/mL</intervention_name>
    <description>Patients will receive subcutaneous (s.c., under the skin) injections of NNC0194-0499 once weekly The study will last for about 19 months</description>
    <arm_group_label>NNC0194-0499 15 mg + semaglutide 2.4 mg</arm_group_label>
    <arm_group_label>NNC0194-0499 30 mg + semaglutide 2.4 mg</arm_group_label>
    <arm_group_label>NNC0194-0499 30 mg + semaglutide placebo 2.4 mg</arm_group_label>
    <arm_group_label>NNC0194-0499 7.5 mg + semaglutide 2.4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (NNC0194-0499)</intervention_name>
    <description>Patients will receive subcutaneous (s.c., under the skin) injections of placebo once weekly The study will last for about 19 months</description>
    <arm_group_label>Placebo (NNC0194-0499) 15 mg + semaglutide placebo 2.4 mg</arm_group_label>
    <arm_group_label>Placebo (NNC0194-0499) 30 mg + semaglutide 2.4 mg</arm_group_label>
    <arm_group_label>Placebo (NNC0194-0499) 30 mg + semaglutide placebo 2.4 mg</arm_group_label>
    <arm_group_label>Placebo (NNC0194-0499) 7.5 mg + semaglutide placebo 2.4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide 3 mg/mL</intervention_name>
    <description>Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide once weekly The study will last for about 19 months</description>
    <arm_group_label>NNC0174-0833 2.4 mg + semaglutide 2.4 mg</arm_group_label>
    <arm_group_label>NNC0194-0499 15 mg + semaglutide 2.4 mg</arm_group_label>
    <arm_group_label>NNC0194-0499 7.5 mg + semaglutide 2.4 mg</arm_group_label>
    <arm_group_label>Placebo (NNC0194-0499) 30 mg + semaglutide 2.4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide placebo</intervention_name>
    <description>Patients will receive subcutaneous (s.c., under the skin) injections of semaglutide placebo once weekly The study will last for about 19 months</description>
    <arm_group_label>NNC0194-0499 30 mg + semaglutide placebo 2.4 mg</arm_group_label>
    <arm_group_label>Placebo (NNC0174-0833) 2.4 mg + semaglutide placebo 2.4 mg</arm_group_label>
    <arm_group_label>Placebo (NNC0194-0499) 15 mg + semaglutide placebo 2.4 mg</arm_group_label>
    <arm_group_label>Placebo (NNC0194-0499) 30 mg + semaglutide placebo 2.4 mg</arm_group_label>
    <arm_group_label>Placebo (NNC0194-0499) 7.5 mg + semaglutide placebo 2.4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0174 0833 10 mg/mL</intervention_name>
    <description>Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 once weekly The study will last for about 19 months</description>
    <arm_group_label>NNC0174-0833 2.4 mg + semaglutide 2.4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0174 0833 placebo</intervention_name>
    <description>Patients will receive subcutaneous (s.c., under the skin) injections of NNC0174-0833 placebo once weekly The study will last for about 19 months</description>
    <arm_group_label>Placebo (NNC0174-0833) 2.4 mg + semaglutide placebo 2.4 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged greater than or equal to 18 years at the time of signing informed consent. In&#xD;
             Republic of Korea, subjects must be aged greater than or equal to 19 years. In Japan,&#xD;
             subjects must be aged greater than or equal to 20 years. In Singapore, subjects must&#xD;
             be aged greater than or equal to 21 years.&#xD;
&#xD;
          -  Histological evidence of NASH based on a central pathologist evaluation of the&#xD;
             baseline liver biopsy. The baseline liver biopsy can be a historical biopsy obtained&#xD;
             within 180 days prior to Visit 1.&#xD;
&#xD;
          -  Histological evidence of fibrosis stage 2, 3 or 4 according to the NASH CRN&#xD;
             classification based on a central pathologist evaluation of the baseline liver biopsy.&#xD;
&#xD;
          -  Histological non-alcoholic fatty liver disease (NAFLD) activity score (NAS) greater&#xD;
             than or equal to 4 for subjects with F2/F3 or greater than or equal to 3 for subjects&#xD;
             with F4 based on a central pathologist evaluation of the baseline liver biopsy. All&#xD;
             subjects must have a score of 1 or more in steatosis, lobular inflammation and&#xD;
             hepatocyte ballooning.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented causes of chronic liver disease other than NAFLD.&#xD;
&#xD;
          -  Positive HBsAg, positive anti-HIV, positive HCV RNA at screening (V2A) or any known&#xD;
             presence of HCV RNA or HBsAg within 2 years of screening (V2A).&#xD;
&#xD;
          -  Presence or history of ascites more than grade 1, variceal bleeding, hepatic&#xD;
             encephalopathy, spontaneous bacterial peritonitis or liver transplantation at V2A.&#xD;
&#xD;
          -  For subjects with F4, presence or history of gastro-oesophageal varices more than or&#xD;
             equal to grade 2 at V3. An oesophagogastroduodenoscopy performed no more than 52 weeks&#xD;
             prior to V3 must be available at V3.&#xD;
&#xD;
          -  Known or suspected excessive consumption of alcohol (more than 20 g/day for women or&#xD;
             more than 30 g/day for men) or alcohol dependence (assessed by the Alcohol Use&#xD;
             Disorders Identification Test (AUDIT questionnaire)).&#xD;
&#xD;
          -  Treatment with vitamin E (at doses more than or equal to 800 IU/day) or pioglitazone&#xD;
             or medications approved for the treatment of NASH which has not been at a stable dose&#xD;
             in the opinion of the investigator in the period from 90 days prior to V2A. In&#xD;
             addition, for subjects with a historical liver biopsy taken more than 90 days prior to&#xD;
             V2A, treatment should be at a stable dose in the opinion of the investigator from time&#xD;
             of biopsy until V2A.&#xD;
&#xD;
          -  Treatment with GLP-1 RAs within 90 days prior to V2A. Subjects with a historical liver&#xD;
             biopsy taken more than 90 days prior to V2A are excluded if they receive treatment&#xD;
             with GLP-1 RAs from time of biopsy until V2A.&#xD;
&#xD;
          -  Treatment with glucose-lowering agent(s) (other than GLP-1 RAs), lipid-lowering&#xD;
             medication or weight loss medication not stable in the opinion of the investigator in&#xD;
             the period from 90 days prior to V2A. In addition, for subjects with a historical&#xD;
             liver biopsy taken more than 90 days prior to V2A, treatment should be at a stable&#xD;
             dose in the opinion of the investigator from time of biopsy until V2A.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-3020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hermitage</city>
        <state>Tennessee</state>
        <zip>37076</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <zip>76301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lyon Cedex 4</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>NICE cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Venissieux</city>
        <zip>69200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>GR-11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Goudi, Athens</city>
        <zip>GR-115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>GR-54621</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>GR-54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>GR-54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jaipur</city>
        <state>Rajasthan</state>
        <zip>302001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Chiba-shi, Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fukui-shi, Fukui</city>
        <zip>918-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamamatsu-shi, Shizuoka</city>
        <zip>431-3192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hatsukaichi-shi, Hiroshima</city>
        <zip>783-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kamigyo-ku, Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kawasaki-shi, Kanagawa</city>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kumamoto-shi, Kumamoto</city>
        <zip>862-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Okayama-shi, Okayama</city>
        <zip>700-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saga-shi, Saga</city>
        <zip>849-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sendai-shi, Miyagi</city>
        <zip>980-0873</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Suita-shi, Osaka</city>
        <zip>564-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toon-shi, Ehime</city>
        <zip>791-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wakayama-shi, Wakayama</city>
        <zip>640-8158</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Yokohama-shi, Kanagawa</city>
        <zip>236-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Daegu</city>
        <zip>42601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gangwon-do</city>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>15355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>06973</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Batu Caves</city>
        <zip>68100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-156</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mysłowice</city>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-326</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-162</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 18, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

